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ABSTRACT (300/350 words) 
Lymph node (LN) metastasis is an important prognostic parameter in breast 
carcinoma, a crucial site for tumour-immune cell interaction and a gateway for further 
dissemination of tumour cells to other metastatic sites. To gain insight into the 
underlying molecular changes from the pre-metastatic, via initial colonisation to the 
fully involved LN, we reviewed transcriptional research along the evolving 
microenvironment of LNs in human breast cancers patients. Gene expression studies 
were compiled and subjected to pathway-based analyses, with an emphasis on 
immune cell related genes. Of 366 studies, 14 performed genomewide gene 
expression comparisons and were divided into six clinical-biological scenarios 
capturing different stages of the metastatic pathway in the LN, as follows: 
metastatically involved LNs are compared to their patient-matched primary breast 
carcinomas (scenario 1) or the normal breast tissue (scenario 2). In scenario 3, 
uninvolved LNs were compared between LN-positive patients and LN-negative 
patients. Scenario 4 homed into the residual uninvolved portion of involved LNs and 
compared it to the patient-matched uninvolved LNs. Scenario 5 contrasted uninvolved 
and involved LNs; whilst in scenario 6 involved (sentinel) LNs were assessed between 
patients with other either positive or negative LNs (non-sentinel).  
Gene lists from these chronological steps of LN metastasis indicated that gene 
patterns reflecting deficiencies in dendritic cells, hyper-proliferation of B cells parallel 
to tumour promoting pathways, including cell adhesion, extracellular matrix 
remodelling, cell motility and DNA repair play key-roles in the changing 
microenvironment of a pro-metastatic to a metastatically involved LN. Similarities 
between uninvolved LNs and the residual uninvolved portion of involved LNs hinted 
that LN alterations expose systemic tumour-related immune responses in breast 
cancer patients. Despite the diverse settings, gene expression patterns at different 
staged of metastatic colonisation in LNs were recognised, and may provide potential 
avenues for clinical interventions to counteract disease progression for breast cancer 
patients. 
 
Keywords: expression, lymph node, premetastatic niche, breast cancer 
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INTRODUCTION 
The lymph nodes (LNs) are functional units of the immune system that act as 
immunological hubs supporting the complex interactions between T cells, B cells, 
antigen presenting cells and stromal cells. LNs receive cells and potential 
immunogenic substances via the afferent lymphatics that drain the tissues and enter 
the LNs at the peripheral subcapsular sinus and also via the high endothelial venules 
which support lymphocyte entry from the blood (1, 2). The LN is a dynamic organ 
capable of undergoing dramatic remodelling, both in terms of architecture and function 
in response to pathological conditions such as inflammation or cancer (3). Many solid 
cancers spread through the lymphatic system to distant organs with the LNs typically 
serving as a first site of seeding outside primary tumour (4-6). For these tumours, the 
presence and extent of LN metastasis are markers of aggressive phenotype, often 
having an inverse linear relationship with prognosis (7-9). In breast carcinoma 
patients, metastasis to LN is an important factor for staging the tumour and routine 
assessment for invasive breast carcinoma patients includes histopathological 
assessment of presence of metastasis, the number of involved LNs and the presence 
or absence of extra-nodal extension (10). 
 
Although the LN is a functional organ for tumour-immune system interaction and acts 
as a read-out for the systemic immune response, molecular characteristics of LNs 
centred around mutational alterations and structural genome rearrangements, 
whereas transcriptional research has been limited in both human and pre-clinical 
models (11). Most studies have aimed to identify molecular signatures associated with 
good and bad prognosis in primary breast tumours (12-18). While the genomes of 
relapsed or secondary breast cancers have revealed that metastases and primary 
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tumour are clonally related, share several driver mutations, and often acquired 
additional novel variants that are not present in the primary lesion (19). 
 
In the metastatic LN, a multitude of factors play important roles in tilting the balance 
between pro-metastatic immunosuppression and anti-tumoural immune response (20-
22). Given the significant implication of LN metastasis for systemic cancer burden, 
surprisingly few emphasis has been given to elucidate the underlying molecular 
signals and cellular alterations of the evolving LN microenvironment between the 
uninvolved (cancer-free) and the involved (metastatic) LNs in breast cancer patients. 
Some of these changes include lymphangiogenesis and increased lymph flow (23), 
recruitment and expansion of immunosuppressive cells (including myeloid-derived 
suppressor cells and regulatory T cells) (24), upregulation of chemokines and 
cytokines, blood vessel remodelling (25, 26) and a lower percentage of effector T cells 
(27). We recently comprehensively histologically characterised diverse immune and 
stromal features in primary tumours and their associated involved and uninvolved 
axillary LNs in a cohort of 309 invasive breast cancer patients (143/309 LN positive) 
(28), and observed that architectural alterations of the uninvolved LN are significant 
predictors for distant metastases. A similar finding of prognostic information from 
examination of the LN architecture was observed in melanoma (29). In preclinical 
mouse models, the involvement of innate lymphoid RORγt+ ILC3 cell, fibroblast 
reticular cells and cancer-associated fibroblasts in the induction of an 
immunosuppressive and pro-metastatic microenvironment in tumour-draining LNs 
was reported (30-32), while uninvolved regional LNs in rats with prostate tumours 
displayed varying degree of genetic changes depending on prostate tumour groups 
and their metastatic capacity (33).  
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With regards to emerging immunotherapy approaches, the LN microenvironment and 
the nature of the immune response have been identified as potent indicators of 
response to therapeutic interventions (34, 35).  With the central position of the LN as 
an immune organ and as a gateway for further dissemination of tumour cells to other 
metastatic sites, we conducted a comprehensive review of existing gene expression-
based research performed on LNs in human breast cancers. We categorised these 
gene expression studies along the evolving microenvironment of axillary metastases. 
By starting with early colonisation to the replacement of the entire LN with metastasis, 
these expression patterns capture information on the molecular mechanisms and 
changes in immune composition that allow the exploration of LNs as a pro-metastatic 
niche. Since the risk of developing distant metastasis and thus overall survival of 
patients with loco-regional metastatic breast cancer is typically poor, it is particularly 
important to establish whether transcriptomic patterns of metastasis might translate 
into new therapeutic strategies, including the successful implementation of 
immunotherapy. 
 
MATERIAL AND METHODS 
Literature Search and Data Collection 
A review of the English literature was performed, focusing on gene expression data 
derived from human LN tissue and the primary lesion in breast cancer patients (if 
matched LN tissue was interrogated), using the combination of the following keywords: 
“breast cancer”, “metastasis”, “lymph nodes” and “gene expression” in “all fields” in 
PUBMED and Ovid MEDLINE ® (accessed on 13th October 2017 and revised on 5th 
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June 2018). All abstracts were manually screened and their methodologies were 
reviewed. Papers were selected if genomewide (i.e. microarray or RNA-sequencing 
based) gene expression analyses of LNs of breast cancer patients were performed 
(n=14). Studies of primary breast tumours and distant metastatic sites, which reported 
only the LN-status of the patients, were excluded (see consort diagram in Figure 1). 
The review was conducted according to the preferred reporting items for systematic 
reviews and meta-analyses (PRISMA) statement (36).  
 
Data analysis 
Of total 366 papers screened, 14 studies were included in the review: Calvo et al. (37), 
Feng et al. (38), Hao et al. (39), Lähdesmäki et al. (40), Weigelt et al. (41), Ellsworth 
et al. (42), Vecchi et al. (43), Suzuki et al. (44), Mathe et al. (45), Zuckerman et al. 
(46), Blackburn et al. (47), Valente et al. (48), Rizwan et al. (49) (all of which performed 
microarray-based gene expression analyses) and Liang et al. (50), (which used 18-27 
million paired-end riboZero RNA-sequencing). Genes with differential expression 
between the respective scenarios were obtained directly from the publications; no cut-
offs were applied (Table 1). Using the biomaRt R package (51, 52) either gene names 
or microarray features were converted to ENSEMBL ID (ENSEMBL GRCh37.p13) (53) 
(Supplementary table 1,2,3). If microarray features could not be mapped (assuming 
that their sequences retired), they were excluded from further studies. Once an 
ENSEMBL ID list was created, HGNC symbols, genomic location and their common 
gene ontology terms were recorded. From these ENSEMBL gene lists, pathway 
analyses were conducted on de-regulated genes using the WebGestalt tool (54) 
(Supplementary table 4). The overrepresentation analysis (ORA) was applied based 
on the Homo sapiens Gene Ontology (GO) biological processes database. The whole 
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genome was used as a reference; all GO terms <0.05 FDR were extracted. To remove 
redundant GO terms, the Revigo tool, with parameter “small” was used (55). The 
resultant GO terms and differentially expressed genes were compared between the 
groups. To capture genes representative for specific immune cell populations, the 
gene-lists compounded from the studies were cross-referenced with published 
immune metagenes (56).  
 
RESULTS AND DISCUSSION 
Overview of expression profiling studies on LNs in Breast Cancer 
A total of 14 genome-wide transcriptomic studies on LN samples were selected, to 
decipher the molecular features of the evolving LN microenvironment as a 
locoregional metastatic site (37-50). Each article published lists of genes specifically 
transcriptionally activated or repressed in LNs, ranging from cancer-free to metastatic 
settings. The cohorts were of mixed-receptor [Estrogen (ER), Progesterone (PR) and 
Human epidermal growth factor receptor (HER2)] invasive breast carcinomas, 
including two studies of invasive carcinomas of ductal/no special type only, and one 
exclusively examining triple negative breast carcinomas (TNBC). To paint a 
chronological picture of the changing microenvironment of the evolving metastatic LN, 
the studies were grouped into six “scenarios”, described below in detail (Table 1, 
Figure 2).  
 
Scenario 1: Comparison between involved LN and primary breast carcinoma, 
the drivers of metastasis: 
                                    Molecular patterns across cancer colonisation in lymph nodes of breast cancer patients 
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With the common aims of searching for drivers of metastatic progression, developing 
metastatic signatures predictive of distant metastasis (38, 43) and identifying 
molecular targets for metastasis-specific therapy or markers of resistance, eight of 14 
studies captured transcriptional alterations between involved LNs and their patient-
matched primary carcinoma. Expression patterns and gene regulatory pathways 
potentially driving metastatic dissemination were determined, while the point of 
acquiring metastatic efficiency in a primary tumour’s timeline was intended to be 
revealed. These studies focussed on the cancerous tissue itself rather than the LN 
microenvironment; thus, the material selected for analyses had at least 70% tumour 
tissue, or laser microdissection was performed.  
 
Although, high transcriptomic similarity between primary carcinoma and its 
corresponding LN metastasis were consistently observed (37, 40-42, 44), genes 
exclusively expressed in either of these two cancerous tissues was reported. Taking 
into consideration the clinical characteristics diversity of these cohorts, we asked 
whether any commonalities among activated or repressed genes could be 
established, potentially pointing collectively to deregulated biological themes. Among 
the eight studies, a total of 88 genes were found to be differentially expressed between 
the involved LN and the primary tumour in at least two studies, while the 
downregulation of 21 genes associated with cell- extracellular matrix (ECM) 
interaction, ECM remodelling, epithelial-mesenchymal transition (EMT) and loss of 
basement membrane function (57, 58) was common to 3 studies was (Supplementary 
table 1 & 2). 
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Downregulation of EMT-associated genes in the involved LN might suggest that, as 
the metastases becomes established, reversal of EMT and restoration to epithelial 
phenotype are essential for the successful colonisation (48). Stromal cells play a 
significant part in this process, particularly matrix metalloproteinases MMP2 and 
MMP7, as these proteins are associated with the breakdown of the ECM, as well as 
innate immune response (59). CD10, a membrane metalloendopeptidase, is present 
at various stages of B cell maturation and of particular importance in LNs, where it is 
strongly expressed by germinal centre B cells, the most highly proliferative lymphocyte 
subset in LNs (60). CD10 was less abundant in involved LNs compared to the primary 
lesions in three studies (37, 42, 43), potentially pointing to a lack of differentiation 
potential of B cells. 
 
Three genes, namely collagenase 11A1 (COL11A1), Asporin (ASPN) and Periostin 
(POSTN) were reported in 4 studies as having lower abundance in involved LNs 
compared to primary tumour tissue (38, 39, 42-44). All three genes function in 
remodelling ECM and ECM-associated protein degradation of the basement 
membrane. ECM remodelling is a well-established mechanistic prerequisite for 
dissemination of the primary cancer and genes involved in ECM are frequently part of 
metastatic gene sets in several other solid tumours (61). COL11A1 promotes cell 
proliferation, migration and tumorigenesis of many human malignancies (62). This 
gene is currently investigated as a diagnostic marker for non-small cell lung carcinoma 
(NSCLC) and, by targeting COL11A1, chemoresistance might be overruled (63). The 
stromal expression of ASPN and POSTN has been shown to be associated with 
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aggressive tumour phenotypes and associated with poor prognosis in prostate and 
colorectal cancers, respectively (64, 65). If their lack of expression in involved LNs 
provides additive risk-information for disease progression warrants further 
investigation. 
 
Complement component 7 (C7), a protein involved in the innate immune system, and 
part of the membrane attack complex that mediates lysis of pathogens, was the only 
gene of higher abundance in involved LNs reported in four studies (38, 42-44). Since 
C7 may be related to processing and responding to different tumour neo-antigens 
present in involved LNs, its presence might reflect attempts of the involved LN to 
counterattack the metastatic colonisation. 
 
Besides the malignant epithelial component, the transcriptional profiles of involved 
LNs almost always still harbour significant signals of immune and stroma cells. Among 
all eight studies, a total of 64 immune cell related genes was identified (Figure 3A & 
3B, supplementary table 5), including upregulation of chemokines, ligands and 
receptors, cytotoxic CD8+ T cells, both immature and activated B cells, T cell receptor 
(TCR)- activation, MHC-class II, TH1 and TH2 in involved LNs. Conversely, genes 
down-regulated in involved LNs were associated with dendritic cells, mast cells and 
monocytes. Dendritic cells are antigen presenting cells that enter the LNs via the 
afferent lymphatics and that prime the effector T cells to initiate adaptive immune 
responses. Germinal centre responses are dependent on T cells activated by dendritic 
cells. A depletion of dendritic cells could represent a major immune escape 
mechanism in cancers (66), due to the lymphangiogenic responses in the metastatic 
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node (67). Thus, a dynamic interplay with the modulation of humoral and cellular 
immune responses, histologically corroborated by the reactive nodal changes with 
follicular, paracortical and sinusoidal hyperplasia is present in these involved LNs (28). 
 
Overall our unifying analyses repeatedly demonstrated a consistent plasticity in 
ECM and immune cells in the metastatic LN tissue, despite the underlying molecular 
similarities between the primary carcinomas and patient-matched involved LNs. 
Cancer genomes reflect on clonal persistence and clonal extinction during cancer 
evolution (19). A recent comprehensive single cell analyses of chemoresistant 
TNBC supported an evolutionary model, in which an adaptive selection in the cancer 
genome is paralleled by an acquired transcriptional program, including ECM 
degradation and EMT (68). Given the remarkable molecular similarities between 
primary lesions and involved LNs, the metastatic genetic programme may be 
activated at an early stage during breast cancer development (15, 69), some 
cancerous cells may acquire their metastatic proficiency late due to clonal evolution 
(70), and as a sum are continually reshaping the metastatic molecular expression 
profiles (44). In parallel, as the metastatic potential of these cells evolves and 
increases over time, and the local microenvironment, through the interaction with 
endothelial, stromal and immune cells, carry significant determinants for successful 
colonisation in the LN.  
 
Scenario 2: Comparison with normal breast tissue, pinpointing the changes in 
metastasis: 
                                    Molecular patterns across cancer colonisation in lymph nodes of breast cancer patients 
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To decipher the remarkable similarities between a breast primary tumour and its LN 
metastasis, Mathe and colleagues (45) made multiple comparisons between normal 
breast tissue, LN-positive primary tumours, LN-negative primary tumours and LN 
metastases. Their hypothesis for identifying genes crucial for metastatic spread relied 
on: (i) genes differently expressed between primary tumour versus normal, tumour-
adjacent breast tissue (NAT) in a LN-positive patient, followed by (ii) genes expressed 
in involved LN compared to normal breast tissue; and then (iii) selecting only those 
genes which were absent in primary tumours versus normal breast tissue in LN-
negative patients. Through this step-wise approach, 14 genes were found commonly 
as downregulated in involved LNs (APOD, MME, OMD, F2RL2, DCN, PTN, SFRP2, 
FMO1, OGN, SRPX, SPARCL1, MMP16, LRRC1, HMCN1) (Supplementary table 3). 
SPRX, SPARCL1, MMP16 and HMCN1 are again involved in cell adhesion, ECM 
breakdown and organisation. DCN influences regulatory T cells (Treg) mediated 
immunosuppression, while CD10, as noted above, is essential for highly proliferative 
and pro-apoptotic germinal centre B cells (60, 71).  
 
Performing an overrepresentation analysis using the GO database (54), pathways 
frequently deregulated in involved LNs in both scenarios 1 and 2 included ossification, 
cell adhesion, ECM organisation, cell proliferation, cell motility, apoptotic process and 
development of vasculature. Remodelling of the ECM and vascular proliferation are 
corroborated by the histological alterations in stromal architecture seen in LNs when 
metastasis manifests itself (Supplementary table 4) and have previously been linked 
to metastasis in multiple solid tumours (72). 
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In parallel, a delicate balance between helper and regulatory T cells seems to create 
a pro-metastatic immunosuppressive niche in the LN, as identified by 7 downregulated 
(EGR1, RBMS3, CD34, IGF1, MEIS2, CMA1, DLC1) and 5 upregulated (MAD2L1, 
STAT1, KIF11, ANLN, DLGAP5) genes associated with specific immune cell 
populations, especially T cell function including helper (RBMS3, DLC1) activated 
(MAD2L1, KIF11, ANLN, DLGAP5) and regulatory T cells. Different subsets of helper 
T cells, including Th17 and the heterogeneity of Tregs, are critical for cancer 
progression and metastasis (73, 74), again emphasising that the balance between 
different subset of helper and regulatory T cells is a crucial factor in successful 
colonisation.  
 
Gene expression patterns across different phenotypical LNs groups: 
By exclusively studying the involved LNs, key questions of: “when” does the LN 
microenvironment develop signals to potentially attract cancer cells, and when, why 
and how these cancer cells can home in such an immune cell-dominant environment, 
are omitted. LNs at different stages of colonisation provide the opportunity to obtain 
an insight in the underlying biology of evolving pre-metastatic setting. The following 4 
scenarios adopted the diverse approaches across nodes of different status (Figure 2): 
Scenario 3: By comparing uninvolved LNs in LN-positive and LN-negative breast 
cancer patients, the premetastatic niche and early genetic aberrations were 
interrogated for changes in immune response, vasculature, and cellular proliferation 
that were potentially measureable even before detectable metastasis had occurred. 
Here, molecular changes specific for a node-to-node manner and alterations 
systemically affect the regional nodes can be determined (46-48). 
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Scenario 4: Comparison between the uninvolved, residual portion of a LN 
bearing metastatic carcinoma with patient matched negative nodes, allowed 
identification of late-stage alterations in the secondary microenvironment, which may 
indirectly support metastatic growth (46, 48). 
Scenario 5: By comparing involved LNs with uninvolved LNs, the alterations of 
immune and stromal cells within similar secondary microenvironment are captured 
(49). 
Scenario 6: By relating positive sentinel LNs in patients with additional, non-
sentinel, positive LNs to patients with additional, non-sentinel, negative LNs, 
genes patterns with increased risk of developing metastasis in other lymph nodes 
might be delineated (50). 
 
Scenario 3: The uninvolved LN, the first step towards metastasis: 
The first step in the colonisation of the LN by tumour cells is potentially the preparation 
of the LN microenvironment, even before the tumour cells arrive. Blackburn et al. (47) 
and Valente et al. (48), investigated the transcriptomic profiles of uninvolved LNs in 
LN-positive and LN-negative patients to identify early preparatory changes in the LN 
microenvironment. Both studies did not observe significant differences in gene 
expression patterns between the uninvolved LNs of LN-positive versus uninvolved 
LNs of LN-negative breast cancer patients(47, 48), and led the authors conclude that: 
(a) the physical presence of metastatic tumour cells may be crucial to elicit a pro-
metastatic niche in the LNs; and (b) these pro-metastatic changes occur in a LN-to-
LN manner and are not reflected systematically in uninvolved LNs in an otherwise LN-
positive patient. 
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Studying the early metastatic changes, Zuckerman et al., followed a different approach 
by purifying immune cells from uninvolved sentinel and non-sentinel LNs. In 
uninvolved LNs (of entirely LN-negative patients), gene patterns were associated with 
immune cell regulation and signalling pathways such as antigen presentation (HLA-
DQA, HLA-A, HLA-DRB3), lymphocyte activation (HLA-DOA, IL23A, IL4, PLCG2, 
TICAM1), cytokine-cytokine receptor interaction (IL12RB2, IL4, CCR8, TNFRSF21, 
IL23A, IL3RA) and pro-inflammatory TREM1 and IL-17 signalling (75, 76), indicating 
an effective antigen processing and anti-tumour response. TREM1 signalling activates 
monocyte-macrophage and neutrophil mediated immune response. IL-17 pathway 
stimulates Th17 cells to respond to a variety of foreign antigens and is involved in 
autoimmune diseases (77). An activation of such pro-inflammatory immune pathways 
in a LN-negative patient’s LNs may facilitate an effective tumour response that 
prevents successful further spreading and colonisation of metastatic cells. In this 
context, breast cancer cells have been shown to hinder the functioning of dendritic 
cells and other antigen-processing cells (78). In contrast, the uninvolved LNs of LN-
positive patients had higher levels of genes involved in relaxin signalling, which 
attracts mononuclear cells to create an immunosuppressive environment (79). The 
lack of effective immune responses, including antigen presentation, together with 
tumour promoting factors may all synergise to establish the necessary 
immunosuppressive pre-metastatic niche in the uninvolved LN of LN-positive patients. 
These molecular alterations may cause various architectural changes, including 
changes in size and location of germinal centres in uninvolved LNs of LN-positive 
breast cancer patients, as we have observed them (28). 
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Scenario 4: Residual portion of an involved LN, a surviving immune 
microenvironment:  
A reflection of the vanishing immune cell microenvironment from the uninvolved to the 
involved LN, is provided by assessment of the residual portion of a LN where some 
colonisation by tumour cells has started (Figure 2 & 4). The uninvolved, ‘normal’ 
residual portion of an otherwise involved LN offers a unique snapshot of direct 
interaction between LN stromal and immune cells with tumour cells. To study the gene 
expression exclusively from this area of the LN, Valente et al. (48) confirmed the 
absence of tumour cells examination with AE1/AE3 immunohistochemical staining and 
laser microdissected the cancer-free tissue for RNA extraction. Similarly, Zuckerman 
and colleagues carefully selected, with flow cytometry-based sorting, only immune 
cells from residual LN materials (46). Most genes downregulated in the residual parts 
of involved LNs, when compared to completely uninvolved LNs, were involved in 
regulation of immune response (HPGDS, STAB2, CLEC4M, PROS1, TFPI), 
advocating a pro-metastatic immunosuppressive microenvironment. STAB2, a 
scavenger receptor, is known to regulate leukocyte trafficking in LNs through 
lymphatic endothelial cells (80), theoretically maintaining defence and tissue 
homeostasis, and in parallel spreading neoplastic cells.  Similarly, in uninvolved LNs 
of otherwise LN-positive patients, pathways downregulated in the residual portion of 
positive LNs were pro-inflammatory immune related pathways like TREM1 signalling 
(NOD2, TLR5), whilst the upregulated pathways were associated with cell cycle 
(RAD51, KIF23, PLK4), DNA repair (RFC2, BRIP1) and tumour promoting 
angiopoietin signalling (RASA1, BRIP1). In residual LN tissue (from nodes with 
metastatic tumour) compared to uninvolved LNs, B cell related genes (AICDA, IGKC, 
IGKV1-5, IGKV3-20), many of them specifically expressed in germinal centres, were 
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highly active. B cells and ectopic germinal centres have previously been linked to 
chronic inflammation and tumour promotion (81, 82), and may represent prognostic 
indicators for developing distant metastases (Figure 2 & 4) (28, 29). The upregulation 
of cell cycle and DNA repair pathways genes can further be linked to germinal centres, 
as these are zones of high proliferation. One might hypothesise, that in uninvolved 
LNs of LN-positive patients and in the residual ‘normal’ part of an involved LN, the 
upregulation of germinal centre B cell genes, in parallel to the dampening of antigen 
presentation and T cell priming, results in an altered tumour-promoting response, 
primarily mediated by B cells. Defective immune regulation in which B cell proliferation 
or humoral response is activated, in spite of the dampening of the antigen presentation 
and leukocyte activation, through some alternate pathways, could create a pro-
metastatic environment. Furthermore, the abundance of kappa light chain genes as 
overexpressed in residual LN tissue point to an alternative B cell activation pathways 
biased towards B cells expressing kappa light chains and of oligoclonal nature. In the 
presence of B cell proliferation, it is essential to study markers such as PD-1, a 
negative regulator of B cell differentiation and expressed by the majority of T cells in 
germinal centres. B cells can both positively and negatively regulate T cell mediated 
antitumor immune responses, however their function in generating a specific pre-
metastatic niche has yet to be established (67). 
 
Scenario 5: From an uninvolved to an involved LN status:  
To study the penultimate step in the evolving LN microenvironment one can look at 
the extreme endpoints, i.e. to capture transcriptional changes in the involved LN as a 
whole and compare with the uninvolved LN. Rizwan and colleagues mainly focussed 
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on change in collagen density in LNs in a murine metastatic breast cancer model, and 
examined expression patterns derived from publicly available microarray-based data 
(GSE4408), in which 16 involved and 3 uninvolved human LNs from breast cancer 
patients were compared (49). Ten of the fourteen genes transcriptionally activated in 
involved LNs, were fibronectin (FN1), three collagen genes (COL1A2, COL1A1, 
COL3A1) and 6 integrin family members (ITGB5, ITGA2, ITGA9, ITGB7, ITGA2B, 
ITGA4). All are key players in cell adhesion, cell-ECM interaction and ECM modulation 
(Supplementary table 3 & 4). Involved LNs displayed increased collagen I and 
basement membrane density in this murine metastatic breast cancer model. Increased 
collagen can promote tumour spread, not only by augmenting cell motility and 
regulating tumour promoting cell-ECM interactions, but also by altering immune 
responses, including switching the phenotypes of macrophages to a tumour-promoting 
M2 type (83) as well as a reduction of B cell follicles (49). 
 
Scenario 6: The final step, can involved LNs send signals to other uninvolved 
LNs to promote tumour dissemination? 
The number of involved LNs in breast cancer is associated with the risk of developing 
distant metastasis (7). The prediction of the extent and number of involved non-
sentinel LNs by assessing the sentinel LN(s) would potentially have practical clinical 
importance, as axillary LN dissection in a group of sentinel LN-positive patients could 
be avoided (84, 85). The study by Liang and colleagues, although performed only on 
6 patients, addressed the question of whether completely replaced LNs, especially the 
sentinel LNs, could send ‘signals’ to uninvolved LNs in preparation to disseminate the 
tumour cells (50). By comparing involved sentinel LNs in patients with additional 
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metastasis in non-sentinel LNs to those with otherwise negative axillary (non-sentinel) 
LNs, tumour promoting pathways were represented in non-sentinel LN-positive group, 
indicated by the expression of kallikrein subfamily members (KLK10, KLK11, KLK12, 
KLK13), proteolysis and steroid receptor signalling. In contrast, genes involved in 
plasma membrane and B cell receptor signalling, including CD22, CD72, Igα, Igβ, 
CD19 and CD21, were depleted in parallel to SYK, LYN, BTK, PTPN6. In the group of 
patients with additional positive LNs, specific gene fusions were noted, especially 
involving IGLL5, a surrogate light chain involved in B cell development (86). Using 
immune metagenes denoting specific immune cell populations (56), an overlap 
between immature and activated B cells (FCRLA, FAM129C, CD22, PAX5), helper T 
cells (SIGLEC10), MDSCs (CEACAM8, FCER2), mast cells (CLC, SIGLEC14) and 
regulatory T cells (CD72, IL9R) (Supplementary table 5) was observed. Taken 
together, a recurrent theme for further tumour cell spreading emerges in these gene 
expression patterns, pointing strongly to a key role of B cells and germinal centres in 
LNs.  
 
LN, a read-out for the systemic immune response? 
Being an early site of tumour dissemination, the LN hosts a variety of tumour-immune 
system interactions. The ultimate question remains whether certain patterns in LNs of 
breast cancer patients’ mirrors changes in the systemic immune response to the 
tumour in the organism. Valente and Blackburn argued that the physical presence of 
cancer cells in the LN is crucial for the pre-metastatic niche development and that the 
changes are therefore not systemic (47, 48). However, much recent research, such 
as the presence of similar immune gene sets in the uninvolved LNs in LN-positive 
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patients and the residual tissue of involved LNs (46), in addition to peripheral blood 
and to some extent in the immune compartment of the primary tumour (46), identified 
changes most likely indicative of a systemic effect in LN-positive patients. In keeping 
with this hypothesis, work on systemic immune responses to effective 
immunotherapies in preclinical murine breast cancer models has proven 
experimentally that changes in the immune composition persist in primary tumours, 
regional LNs, peripheral blood, bone marrow and other lymphoid organs (35). 
 
Limitations 
Despite the scarcity of expression data from LN tissue of breast cancer patients, 
together these data expose snap-shots of the steps in the molecular transitions that 
occur, starting from the uninvolved LN in LN-positive patients, to uninvolved residual 
tissue of involved LNs, to fully involved LNs, and finally the pro-disseminating signals 
in involved LNs. Ideally, all these comparisons should be examined within an individual 
patient’s samples, to exclude patient-to-patient heterogeneity. Genomewide studies 
of whole LN samples mask effects in this highly spatially organised immune organ. 
Using sophisticated imaging technologies or single cell -omics analyses to capture 
earliest stages of LN metastasis, i.e. when tumour cells enter through the afferent 
lymphatic vessels and colonise in the subcapsular sinus (87), would provide valuable 
biological and potentially clinical relevant information. 
 
CONCLUSION 
The prognostic relevance of changes in uninvolved LNs is tantalising as it highlights 
the need of studying the interconnected roles of immune, stromal and endothelial cells 
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within this small immune organ as well as the whole immune system (28, 29). With the 
recent findings of the systemic orchestration of immune cells with effective 
immunotherapy (35), examination of local plus systemic tumour-immune cell 
interactions might hold the key for successful immunotherapeutic strategies. Although 
some patterns are evident from close scrutiny of existing literature, the ‘premetastatic’ 
LN represents an unmet knowledge gap; comprehensive cellular and molecular 
studies focusing on changes in different immune cell compartments at different time-
points during the development of metastasis are needed to unlock this complicated 
biological process, both from a mechanistic and therapeutic point of view.  
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Table 1: Genomewide expression studies of LNs of breast carcinoma patients. 
 
  
CLINICAL 
QUESTION 
STUDY BREAST 
CARCINOMA  
SAMPLE COHORT RESULTS 
Scenario 1 
Involved lymph node 
(ILN) versus primary 
tumours (PT) 
Calvo et al. (37), 2013 IDC 18 PT vs matching 
ILN 
 
Infrequent loss of luminal 
differentiation in metastatic 
LN 
Feng et al. (38), 2007 
 
IDC 26 PT vs matching 
ILN 
 
79 DEG 
Hao et al. & 
Lähdesmäki et al.(39, 
40), 2004 
Invasive BC 9 PT vs matching 
ILN 
 
 
280 DEG 
Weigelt et al (41), 2005 Invasive BC 15 PT vs matching 
ILN 
 
No classifier or single gene 
could discriminate  
Ellsworth et al. (42), 
2009 
Invasive BC 20 PT vs matching 
ILN 
 
51 DEG 
Vecchi et al. (43), 2008 Invasive BC 26 PT vs matching 
ILN 
 
270 DEG 
Suzuki et al. (44), 2007 Invasive BC 10 PT vs matching 
ILN 
 
84 DEG 
Scenario 2 
Involved LN versus 
normal adjacent 
breast tissue (NAT)  
 
Mathe et al. (45), 2015 TNBC 15 ILN vs 17 NAT 83 genes were significantly 
associated with LN 
metastasis 
Scenario 3 
Uninvolved LN in LN-
positive versus LN-
negative patients 
Zuckerman et al. (46), 
2013 
Invasive BC 11 PT, 30 LN, 21 
PB 
116/ 219 DEG (SLN/ NSLN 
respectively) 
Blackburn et al. (47), 
2017 
Invasive BC 24 LN from NP vs 
40 LN from NN 
 
No genes were 
differentially expressed 
with stringent FDR 
 
Scenario 4 
Uninvolved residual 
portion of involved 
LN versus uninvolved 
LN 
Valente et al. (48), 2014 Invasive BC 20 matched pairs 
of involved and 
uninvolved LN 
22 DEG 
Zuckerman et al. (46), 
2013 
Invasive BC 11 PT, 30 LN, 21 
PB 
 
103 DEG  
Scenario 5 
Involved LN versus 
uninvolved LN 
 
 
Rizwan et al. (49), 2015 
 
Invasive BC 
 
16 involved vs 3 
uninvolved LN 
 
13 DEG 
Scenario 6 
Positive sentinel LNs 
in patients with 
additional, non-
sentinel, positive LNs 
to patients with 
additional, non-
sentinel, negative 
LNs 
Liang et al. (50), 2015 Invasive BC 3 NSLN+ SLN vs 3 
NSLN- SLN 
160 DEG 
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Figure legends  
Figure 1: Systematic review flowchart in accordance to the PRISMA statement 
(36) for the gene expression studies performed on LNs in human breast cancer 
patients. Total 14 studies were included after the procedure of searching, screening 
and excluding from the English literature database. Thirteen of these studies were 
subjected to quantitative analysis. 
 
Figure 2: Different scenarios studying lymph nodes, breast cancers and normal 
tissue. Six scenario depicted different comparisons (indicated by green arrows) = 
Scenario 1: involved lymph node versus primary tumour (# of studies= 8); Scenario 2: 
involved lymph node versus normal breast tissue (# of studies= 1); Scenario 3: 
uninvolved LNs in LN-positive patients versus uninvolved LNs in LN-negative patients 
(# of studies= 2); Scenario 4: uninvolved residual portion of involved LN versus patient-
matched uninvolved LN (# of studies= 2); Scenario 5: involved LN versus patient-
matched uninvolved LNs (# of studies= 1); Scenario 6: involved sentinel LNs in 
patients with additional, non-sentinel, positive LNs versus involved sentinel LNs in 
patients with additional, non-sentinel, negative LNs (# of studies= 1). Tumours are 
shown in orange, red and green denote involved and uninvolved LNs, respectively. In 
scenario 4, the shaded portion represents the uninvolved residual portion of an 
involved LN. 
 
Figure 3: Immune cell composition in different scenarios. A: The percentage of 
genes representing specific immune cell populations in each of the scenarios is 
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shown. B. The proportion of different immune cell populations among all the immune-
related genes in each scenario. (Scenario 4 was omitted, as reported 103 differentially 
expressed genes could not be retrieved from the original study). 
 
Figure 4: Chronological steps of lymph node metastasis (H&E stain). (A) An 
uninvolved axillary LN with no evidence of tumour cells (0.7X). (B) Partial colonisation 
of a LN with significant amount of residual uninvolved LN tissue (black arrowhead) and 
two nodules of metastasis (black arrows) are depicted (0.5X). Inset shows tumour cells 
mixed with background immune cells (20X). (C) A lymph node with near total 
replacement of normal lymph nodal tissue (1X). The inset displays a higher power 
magnification of tumour cells (10X). All images were captured by Nanozoomer and 
viewed in NDP.view2 software (Hamamatsu). 
 
Table 1: Genomewide expression studies of LNs of breast carcinoma patients. 
BC = Breast carcinoma, DEG = Differentially expressed genes, IDC = Invasive ductal 
carcinoma (no special type), ILN = Involved LN, LN = lymph node, NAT = Normal 
adjacent breast tissue, NN = Node negative patients, NP = Node positive patients, 
NSLN = Non-sentinel lymph node, PT = Primary tumour, SLN = Sentinel lymph node. 
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Supplementary information 
Supplementary table 1: Gene list compiled from all the studies included in scenario 1 
(Involved LN versus primary breast tumour). 
 
Supplementary table 2: List of genes found to be differentially expressed in multiple 
studies included in scenario 1 (Involved LN versus primary breast tumour). 
 
Supplementary table 3: Fully compiled gene list across all scenarios. 
 
Supplementary table 4: Pathway-based analysis of the differentially expressed genes 
across all the scenarios. 
 
Supplementary table 5: Differentially expressed genes representing specific immune 
cell populations across all the scenarios. 
 
